|
The Network Pharmacology Company |
e-Therapeutics is a drug discovery and development company based in Oxford and Newcastle, UK. The Company is a pioneer of network pharmacology, a distinctive new approach to the discovery of medicines.
It has a clinical pipeline of two drugs, ETS2101, which is in phase I trials for cancer, and ETS6103, which is in phase II development for depression
e-Therapeutics is listed on AIM with the ticker symbol ETX |
|
 British Prime Minister David Cameron and Prof. Malcolm Young, CEO of e-Therapeutics, shake hands as the Prime Minister opens our drug discovery centre at Oxford. more |
|
e-Therapeutics to raise £40m |
|
|
ETS2101 solid tumour trial |
|
e-Therapeutics plc announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101.
The full article can be read here.
|
|
|
Latest corporate presentation |
|
|
